Institute for Clinical and Economic Review (ICER) Calls for Public Comments to Improve Value Assessm

The Institute for Clinical and Economic Review (ICER) is currently conducting a review of disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis. ICER assesses the value of medications by considering price, how well a medication works compared to others, quality adjusted life years (QALYs) and other cost-effectiveness factors through a value assessment framework. ICER has called for public comments to suggest improvements to this framework. Please submit your comments — the site also includes a video titled "What Does ICER Do?" The National MS Society recently suggested improvements for…

Favicon of da :

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati